Company reported strong clinical efficacy data for both lead programs with high response rates, durable responses, and favorable safety profiles. The data supports advancement toward potential regulatory approval and commercialization of off-the-shelf CAR-T therapies, which could address significant unmet medical needs in hematologic malignancies.
The company reported strong clinical efficacy data for CB-011 with high response rates (83% CR, 91% MRD negativity), durable responses at 15 months, manageable safety profile, and positive results even in a patient previously treated with competing CAR-T therapy. These results support the therapeutic potential and competitive positioning of the drug candidate.
Articles that tag CRBU but are mainly about other companies.
Zacks Rank #2 (Buy) with 20.08% average earnings surprise over past four quarters, meeting criteria for earnings beat potential
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
